We are live on ! Find out more
FFM

Fairmount Funds Management Portfolio holdings

AUM $1.38B
1-Year Est. Return 407.79%
This Fund
S&P 500
This Quarter Est. Return
-10.23%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$243M
AUM Growth
+$5.99M
Cap. Flow
+$33.2M
Cap. Flow %
13.63%
Top 10 Hldgs %
76.36%
Holding
21
New
–
Increased
13
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$10.4M
2
INSM icon
Insmed
INSM
+$9.56M
3
ATXS
Astria Therapeutics
ATXS
+$8.74M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$8.28M
5
ARGX icon
argenx
ARGX
+$5.03M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.6M
2
MCRB icon
Seres Therapeutics
MCRB
+$7.27M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$4.02M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$1.56M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$192K

Sector Composition

Rank Sector Weight
1 Healthcare 96.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$23.3B
$36.5M 15.02%
1,283,887
+322,090
+33% +$9.56M
ZGNX
2
DELISTED
Zogenix, Inc.
ZGNX
$34M 14%
1,970,259
+565,000
+40% +$10.4M
AXSM icon
3
Axsome Therapeutics
AXSM
$12.2B
$21.1M 8.67%
312,598
+61,000
+24% +$3.66M
ARGX icon
4
argenx
ARGX
$53.7B
$20.8M 8.56%
69,144
+17,694
+34% +$5.03M
IOVA icon
5
Iovance Biotherapeutics
IOVA
$2.08B
$13.2M 5.41%
505,890
-60,000
-11% -$1.56M
TIL icon
6
Instil Bio
TIL
$50.9M
$13M 5.35%
33,695
+6,195
+23% +$2.3M
ALLK
7
DELISTED
Allakos
ALLK
$13M 5.34%
152,162
+4,500
+3% +$449K
COGT icon
8
Cogent Biosciences
COGT
$6.48B
$12.6M 5.2%
1,558,975
– –
AMRN
9
Amarin Corp
AMRN
$297M
$11.1M 4.56%
126,662
+46,250
+58% +$4.54M
ACAD icon
10
Acadia Pharmaceuticals
ACAD
$4.39B
$10.3M 4.25%
423,817
-8,500
-2% -$192K
PNT
11
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$8.88M 3.65%
864,214
+814,214
+1,628% +$8.28M
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
$8.69M 3.57%
896,281
-426,900
-32% -$4.02M
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$8.63M 3.55%
682,028
+673,167
+7,597% +$8.74M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$8.57M 3.52%
888,980
+100,000
+13% +$976K
ENTA icon
15
Enanta Pharmaceuticals
ENTA
$384M
$7.84M 3.22%
178,058
+6,911
+4% +$338K
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.35M 3.02%
210,000
+35,000
+20% +$1.37M
KROS icon
17
Keros Therapeutics
KROS
$210M
$6.34M 2.61%
149,333
+40,000
+37% +$2.17M
VRDN icon
18
Viridian Therapeutics
VRDN
$1.99B
$642K 0.26%
35,092
– –
VRNA
19
DELISTED
Verona Pharma
VRNA
$549K 0.23%
83,944
– –
MCRB icon
20
Seres Therapeutics
MCRB
$50.2M
– –
-17,651
Closed -$7.27M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-67,800
Closed -$11.6M

Similar funds

NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.38B AUM 39.2% 1-Year Est. Return
AO
Advisor OS Chicago, Illinois $1.38B AUM 16.6% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return

Fairmount Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Fairmount Funds Management held 21 positions worth $243M, up 2.5% from $237M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Fairmount Funds Management deployed $33.2M of net new capital in Q2 2021, adding to 13 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Trillium Therapeutics Inc., an estimated $4.02M trimmed.

  • Fairmount Funds Management added most to Zogenix, Inc. in Q2 2021, an estimated $10.4M increase.
  • Fairmount Funds Management's biggest Q2 2021 reduction was Trillium Therapeutics Inc., cutting an estimated $4.02M.
  • Fairmount Funds Management fully exited Mirati Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $11.6M.
  • Fairmount Funds Management's ten largest holdings make up 76% of its $243M portfolio in Q2 2021.
  • Fairmount Funds Management opened 0 new positions and closed 2 in Q2 2021.
  • Fairmount Funds Management's portfolio value rose 2.5% quarter-over-quarter to $243M.

Based on Fairmount Funds Management's 13F filing for Q2 2021, filed 13 Aug 2021.